Literature DB >> 9950894

Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level.

G Gurujeyalakshmi1, M A Hollinger, S N Giri.   

Abstract

Pirfenidone (PD) is known for its antifibrotic effects in the bleomycin (BL) hamster model of lung fibrosis. We evaluated whether pretreatment of hamsters with PD could influence the effects of BL-induced overexpression of platelet-derived growth factor (PDGF)-A and PDGF-B genes and proteins in the same model of lung fibrosis. We demonstrate elevated levels of PDGF-A and PDGF-B mRNAs in bronchoalveolar lavage (BAL) cells from lungs of BL-treated compared with saline control hamsters by RT-PCR analysis. However, these levels were not altered in BAL cells obtained from BL-treated hamsters on diets containing 0.5% PD. Western blot analysis of BAL fluid for PDGF isoforms demonstrated that PD treatment inhibited the synthesis of both PDGF-A and PDGF-B isoforms. PD treatment also decreased the mitogenic activity in the BAL fluid from BL-treated hamster lungs. Taken together, these data provide evidence that the protective effects of PD against BL-induced lung fibrosis may be mediated by a reduction in PDGF isoforms produced by lung macrophages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950894     DOI: 10.1152/ajplung.1999.276.2.L311

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  47 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Phf14, a novel regulator of mesenchyme growth via platelet-derived growth factor (PDGF) receptor-α.

Authors:  Michinori Kitagawa; Atsushi Takebe; Yuichi Ono; Toshio Imai; Kazuki Nakao; Shin-Ichi Nishikawa; Takumi Era
Journal:  J Biol Chem       Date:  2012-06-23       Impact factor: 5.157

Review 3.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

Review 4.  The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not.

Authors:  Yael Aschner; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

5.  Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma.

Authors:  Ryota Kurimoto; Takahiro Ebata; Shunichiro Iwasawa; Tsukasa Ishiwata; Yuji Tada; Koichiro Tatsumi; Yuichi Takiguchi
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

Review 6.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.

Authors:  Gary A Visner; Fengzhi Liu; Peyman Bizargity; Hanzhong Liu; Kaifeng Liu; Jun Yang; Liqing Wang; Wayne W Hancock
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

Review 8.  Pirfenidone: in idiopathic pulmonary fibrosis.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

Review 9.  Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review.

Authors:  Nadim Srour; Bernard Thébaud
Journal:  Stem Cells Transl Med       Date:  2015-10-22       Impact factor: 6.940

10.  The multifaceted role of pirfenidone and its novel targets.

Authors:  José Macías-Barragán; Ana Sandoval-Rodríguez; Jose Navarro-Partida; Juan Armendáriz-Borunda
Journal:  Fibrogenesis Tissue Repair       Date:  2010-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.